Neutropenia in myelosuppressed cancer patients treated with recombinant human erythropoietin (EPO)
Journal of Clinical and Experimental Hematology · 2026
DOI: 10.46439/hematol.5.034 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Clinical and Experimental Hematology, 2026. Verfasst von Daniel G. Wright und 2 weiteren Autor:innen. Die Arbeit nennt 32 Literaturangaben.
Themen: Onkologische Pflege
Abstract (Originalsprache)
Recombinant human erythropoietin (EPO) has been used extensively for over 3 decades to treat anemia, including that associated with cancer treatment. Multiple randomized clinical trials have found that EPO treatment ameliorates anemia and reduces transfusion requirements in cancer patients undergoing chemotherapy. However, reports of some trials suggested that EPO treatment might also exacerbate neutropenia, as anticipated by pre-clinical observations that EPO suppresses neutrophil production in short- and long-term marrow cultures. However, neutropenia was expected in these trials and not reported in detail. Recently, primary data from 5 industry-sponsored trials of EPO treatment in cancer patients became available through the Yale Open Data Access (YODA) project, allowing us to examine serial absolute neutrophil counts (ANCs) from 1650 cancer patients randomized to EPO or placebo treatment. The incidence of severe neutropenia (ANCs
Zitieren
APA
Wright, D. G., Wright, E. C., & Noguchi, C. T. (2026). Neutropenia in myelosuppressed cancer patients treated with recombinant human erythropoietin (EPO). Journal of Clinical and Experimental Hematology. https://doi.org/10.46439/hematol.5.034
Vancouver
Wright DG, Wright EC, Noguchi CT. Neutropenia in myelosuppressed cancer patients treated with recombinant human erythropoietin (EPO). Journal of Clinical and Experimental Hematology. 2026. doi:10.46439/hematol.5.034
BibTeX
@article{Wright2026,
author = {Wright, Daniel G. and Wright, Elizabeth C. and Noguchi, Constance T.},
title = {Neutropenia in myelosuppressed cancer patients treated with recombinant human erythropoietin (EPO)},
journal = {Journal of Clinical and Experimental Hematology},
year = {2026},
doi = {10.46439/hematol.5.034}
}
EUVIMED